Abstract-
I. INTRODUCTION
Cells are the structural and functional unit of living organisms. The cellular physiological states are closely related to human health and diseases. The unique biochemical and biophysical properties enable a cell to fulfill its specific functions and physiological changes within a cell are often accompanied by chemical and physical alterations and reorganization in the cell [1] . For example, compared with healthy red blood cells (RBCs), pathological RBCs from sickle-cell anemia patients are found to be stiffer and more viscous [2] . Hence, detecting the physiological features of cells is important for us to understand the underlying mechanisms that guide the development of diseases. Traditional studies about investigating cellular physiological features are based on analyzing the chemical properties of cells (e.g., gene mutations, protein expression levels, molecular conformation, changes of ion concentrations and cellular components) via various biochemical methods, e.g., polymerase chain reaction, western blotting, X-ray crystallography, nuclear magnetic resonance, and flow cytometry [3] . The disadvantage of these methods is that they require the lysis of cells, which destroys the natural structures of cells. For visualizing the cellular morphology, optical microscopy cannot reveal the nanostructures due to the limit of 200 nm spatial resolution; while electron microscopy requires that cells be fixed and dried, thus cannot observe the nanostructures of living cells [4] . The advent of atomic force microscopy (AFM) [5] in 1986 provides a novel and powerful instrument for detecting cellular physiological activities. AFM has excellent advantages, such as nanometer spatial resolution, can work in liquids and label-free (without the need for fixing, staining, or labeling of the cells), allowing it to noninvasively visualize the natural nanostructures of living cells at the singlemolecule level [6, 7] . AFM is the only tool that can directly locate and manipulate single native biomolecules on the surface of living cells [8] . Besides imaging the surface topography of biological specimens, AFM can simultaneously acquire multiple physical parameters which can be used to indicate the cell states, e.g., mechanical properties, energy dissipation, deformation, adhesion, and molecular interactions [9] . The rapid development of high-speed AFM in the past decade has decreased the time of recording an image to millisecond time-scale [10] , allowing us to visualize the realtime morphological changes of cellular fine structures [11] and the conformational changes of single native molecules at the nanoscale [12] . So far AFM has become an important platform in the field of life sciences, greatly complementary to the traditional biochemical methods.
In the past decade, researchers have widely used AFM to investigate the physiological activities at single-cell and singlemolecule levels, providing a lot of novel insights into cell biology and related diseases. These results undoubtedly greatly improve our understanding of the cellular behaviors at the nanoscale. However, it should be pointed out that these studies were commonly performed on isolated molecules from cell lines cultured in vitro [13, 14] or directly on cell lines [7, 9] . We know that cells cultured in vitro are quite different from the cells in vivo because of the huge difference between in vivo 3-d environment and 2-d in vitro environment [15] . For cells cultured in vitro, they lose the neurohumoral regulation and cell-cell interactions, which result in the significant changes of cell structures and functions [16] . Especially in the era of personalize medicine, exact diagnosis of individual patients plays a crucial role. This requires us to thoroughly understand the disease states. However, due to the fact that current laboratory studies about the underlying mechanisms of cancers and therapeutic agents are commonly performed on cells cultured in vitro, the results cannot fully reflect the actual situations taking place in the real-world clinical environments [17] , greatly hindering the development of novel drugs with enhanced potency. Viewed from this point, in order to better understand cancers from more aspects, directly investigating the tumor cells from clinical cancer patients using AFM single-cell and single-molecule techniques is evidently of practical significance.
II. RECOGNIZING TUMOR CELLS FROM CLINICAL LYMPHOMA PATIENTS
Lymphomas are solid tumors of the immune system and 90% of lymphomas are non-Hodgkin lymphoma [18] . About 85% of non-Hodgkin lymphomas in adults are of B cell origin [19] . Rituximab is the first monoclonal antibody approved by USFDA for treating a human cancer -B-cell lymphomas. The target of rituximab is the CD20 antigen molecule which is highly expressed on B-cell lymphomas. The use of rituximab (especially combined with chemotherapy) in practice greatly improves the survival rates of lymphoma patients. Combining rituximab with chemotherapy is now the standard therapy for most B-cell lymphomas. However, there are still many patients who develop resistance to rituximab. Besides, rituximab therapy can result in adverse effects to the patients and some are serious, such as hypotension, rigors, bronchospasm, and angioedema [20] . Hence, in order to avoid the unnecessary cost and protect patients from the rituximab-induced adverse effects, an important issue in the current lymphoma targeted therapy is identifying the patients who can benefit from rituximab therapy. This requires us to have a thorough understanding of the underlying mechanisms of rituximab. However, current studies about rituximab's killing mechanisms are commonly based on the ensemble experiments which can not reveal the detailed situations at the nanoscale. Quantitatively investigating the rituximab's actions at single-cell and single-molecule levels is still scarce. In order to address this issue, we used AFM to investigate the CD20-rituximab interactions directly on tumor cells prepared from clinical lymphoma patients.
The prerequisite of using AFM to probe the clinical tumor cells is recognizing the tumor cells from the biopsy samples of the patients. The biopsy samples (such as bone marrow) contain both tumor cells and healthy cells and the tumor cells are a minority population. Traditional studies about isolating lymphoma tumor cells by flow cytometry use CD19, CD20 or CD40 antibodies [21, 22] . However, healthy B cells also express these molecules. Thus, the results of traditional studies contain healthy B cells. Recently, studies have shown that the receptor tyrosine kinase-like orphan receptor 1 (ROR1) is a specific biomarker which is expressed on the surface of chronic lymphocytic leukemia and B-cell lymphomas but not on all healthy cells (including healthy B cells) [23] . Thus, ROR1 is an adequate biomarker for identifying the malignant B cells. We used ROR1 fluorescence labeling to recognize the tumor cells from the biopsy samples of clinical lymphoma patients. The goat-anti-human-ROR1 antibody was purchased from R&D Systems (Minneapolis, USA). The FITC-labeled donkeyanti-goat IgG was used as secondary antibody. We first performed ROR1 fluorescence labeling experiments on B-cell lymphoma Raji cell line [16] , and the results are shown in Fig.  1 . Fig. 1 (A, B) are the optical bright field image and ROR1 fluorescence image of the control group (without ROR1 antibody), respectively. The fluorescence was dark, and this was because that ROR1 was not added. Fig. 1(C, D) are the optical bright field image and ROR1 fluorescence image of the ROR1 group (with ROR1 antibody). We can see that nearly all Raji cells exhibited bright fluorescence. This was because that Raji cells express ROR1 on the cell surface. The results of Fig. 1 demonstrated the feasibility of ROR1 fluorescence labeling to recognize tumor B cells. Then the established procedure was applied on the bone marrow cell samples prepared from a clinical B-cell lymphoma patient [24] , as shown in Fig. 2. Fig. 2(A, B) are the optical bright field image and ROR1 fluorescence image of peripheral blood cells from healthy volunteers respectively. There was no fluorescence and this was because that healthy volunteers did not have tumor cells in the blood. Fig. 2(C, D) are the optical bright field image and ROR1 fluorescence image of bone marrow cells from a B-cell lymphoma patient with bone marrow invasion respectively. We can see that several cells exhibited fluorescence. For the lymphoma patient, tumor cells had invaded the bone marrow and thus there was tumor cells in the bone marrow. But the number of tumor cells was small compared with healthy cells, and thus we can see only a few cells with fluorescence.
III. IMAGING LYMPHOMA PATIENT TUMOR CELLS USING AFM
Based on the ROR1 fluorescence recognition of the tumor cells in the bone marrow cell samples from the lymphoma patients, the morphology of lymphoma patient tumor cells was acquired by AFM imaging [25] , as shown in Fig. 3. Fig. 3(A, B) are optical bright field image and fluorescence image of the bone marrow sample respectively. From the bright field image, we can see five cells. From the fluorescence image, only one cell exhibited fluorescence, indicating that it was a tumor cell. Under the guidance of fluorescence, AFM tip was moved to the tumor cell to image its morphology. Fig. 3(C, D) are the AFM height image and deflection image of the tumor cell respectively. We can see that tumor cell was significantly larger than healthy cells. This is because that when a healthy cell becomes cancerous, its shape and structure change significantly, for example, its nuclear volume becomes larger and the nuclear contour becomes irregular [26] . This alterations in the tumor cell may cause that the size of tumor cell is larger than the size of healthy cell. It should be pointed that the images in Fig. 3 were acquired on chemically fixed cells. In future, we plan to image the living lymphoma patient tumor cell. Because lymphoma cell is a type of suspended cell, we need to immobilize them to the substrate before acquiring AFM images. Imaging living patient tumor cell will allow us to monitor the dynamical changes of cellular nanostructures. 
IV. PROBING INDIVIDUAL CD20 MOLECULES ON LYMPHOMA PATIENT TUMOR CELLS USING AFM
By AFM single-molecule force spectroscopy (SMFS), the CD20 molecules were probed directly on lymphoma patient tumor cells. For SMFS measurements, rituximabs were linked to the AFM tip via polyethylene glycol (PEG) linker molecules. Under the guidance of ROR1 fluorescence, the AFM tip carrying rituximabs was moved to the tumor cell and then force curves were recorded on cell surface. Fig. 4 shows the binding affinity of CD20-rituximab on lymphoma patient tumor cell. Fig. 4A is a typical force curve obtained on tumor cell. We can clearly see that there was a specific unbinding peak in the retract curve. The unbinding peak was caused by the stretching of the PEG molecule which has non-linear elasticity. For contrast, force curves were also recorded on healthy cells (the cells did not exhibit ROR1 fluorescence), as shown in Fig. 4B . We can see that there was a tiny non-specific unbinding peak in the retract curve. Fig. 4C , D are the histogram of CD20-rituximab specific binding forces and non-specific binding forces respectively, showing that the CD20-rituximab specific binding force (57±28 pN) was remarkably larger than that of non-specific binding force (21±7 pN). By obtaining 16×16 force curves at the local areas (500×500 nm 2 ) of tumor cells, the distributions of CD20s were mapped. For each force curve, one binding force is calculated. After normalizing the binding forces into 0~255, the gray maps were constructed, as shown in Fig. 5 . From the gray maps on tumor cells, we could see many gray and bright pixels which reflected the distributions of CD20s. For contrast, arrays of force curves were also recorded on healthy cells (red blood cells). Because red blood cells have a special shape, that is, oval biconcave disk. We can distinctly discern them from the AFM images. Thus we used red blood cells as healthy cells. From the gray maps (Fig. 5) , we can see that there were few gray and bright pixels on healthy cells. This is because that red blood cells do not express CD20s. The results in Fig. 5 also show that the distributions of CD20s on the surface of tumor cells are heterogeneous. Some CD20s assembled together to form nano-clusters, while some CD20s distributed dispersedly. We know cell surface is highly heterogeneous caused by the existence of lipid rafts [27] . Besides, studies have shown that CD20s are organized into dimers or tetramers on the cell surface [28] . All of these factors may be related to the heterogeneous distributions observed by AFM. All together, the AFM results directly visualize the nanoscale distributions of CD20s, improving our understanding of CD20. Fig. 5 Mapping CD20s on lymphoma patient tumor cells [24] . The color scale (from black to white) corresponds the binding force 0~100 pN.
V. CONCLUSION
This work has demonstrated the use of AFM to quantify the binding affinity and nanoscale distributions of individual target proteins directly on lymphoma patient tumor cells under the fluorescent assistance of specific tumor cell surface marker. The study offers a novel approach to investigate the target proteins directly on clinical cancer cells at the nanoscale, potentially having impacts on drug evaluation and efficacy prediction.
